In our previous study [29], we identified a subgroup of patients with elevated proportions of activated regulatory T-cells (aTregs) among CD4+FOXP3+ T-cells at the initiation of therapy; this group experienced more frequent episodes of severe infections during follow-up. The gene discussed is CD4; the disease is infection.